NasdaqCM:CPRXBiotechs
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story
Catalyst Pharmaceuticals, ticker NasdaqCM:CPRX, has agreed to be acquired by Angelini Pharma in a definitive all cash transaction.
The company has settled all pending Firdapse patent litigation, granting generic licenses that run through 2035.
The deal marks an exit for current public shareholders and is set to reshape how Catalyst Pharmaceuticals operates within the rare disease drug market.
Catalyst Pharmaceuticals focuses on treatments for rare neurological conditions, with Firdapse as a...